Literature DB >> 29659925

Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas.

Alexis Desrichard1,2, Fengshen Kuo1, Diego Chowell1,2, Ken-Wing Lee1,2, Nadeem Riaz1,3, Richard J Wong4, Timothy A Chan1,2,3, Luc G T Morris1,2,4.   

Abstract

Background: Tobacco smoking creates DNA damage, inducing mutations and potentially altering the tumor immune microenvironment. These types of genetic and immune microenvironment alterations are critical factors known to affect tumor response to immunotherapy. Here we analyze the association between the mutational signature of tobacco smoking, tumor mutational load, and metrics of immune activity in squamous cell carcinomas arising in the head and neck and lung.
Methods: Using RNA and DNA sequencing data from The Cancer Genome Atlas head and neck (HNSC; n = 287) and lung (LUSC; n = 130) squamous cell carcinoma data sets and two independent gene expression data sets (HNSC, n = 136; LUSC, n = 75), we examined associations between the mutational smoking signature, mutation count, immune cell infiltration, cytolytic activity, and interferon-γ signaling.
Results: An increasing mutational smoking signature was associated with statistically significantly increased overall mutational load in both HNSC (ρ = .33, P = 1.01 × 10-7) and LUSC (ρ = .49, P = 2.80 × 10-9). In HNSC, a higher mutational smoking signature was associated with lower levels of immune infiltration (ρ = -.37, P = 1.29 × 10-10), cytolytic activity (ρ = -.28, P = 4.07 × 10-6), and interferon-γ pathway signaling (ρ = .39, P = 3.20 × 10-11). In LUSC, these associations were reversed (ρ = .19, P = .03; ρ = .20, P = .02; and ρ = .18, P = .047, respectively). Differentially expressed genes between smoking-high and smoking-low tumors revealed broad tobacco-induced immunosuppression in HNSC, in contrast to a tumor-inflamed microenvironment in smokers with LUSC. Conclusions: In squamous cell carcinomas, the genetic smoking signature is associated with higher mutational load, but variable effects on tumor immunity can occur, depending on anatomic site. In HNSC, smoking is predominantly immunosuppressive; in LUSC, more pro-inflammatory. Both tumor mutation load and immune microenvironment affect clinical response to immunotherapy. Thus, the mutational smoking signature is likely to have relevance for immunotherapeutic investigation in smoking-associated cancers.

Entities:  

Mesh:

Year:  2018        PMID: 29659925      PMCID: PMC6292793          DOI: 10.1093/jnci/djy060

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  25 in total

1.  First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Authors:  David P Carbone; Martin Reck; Luis Paz-Ares; Benjamin Creelan; Leora Horn; Martin Steins; Enriqueta Felip; Michel M van den Heuvel; Tudor-Eliade Ciuleanu; Firas Badin; Neal Ready; T Jeroen N Hiltermann; Suresh Nair; Rosalyn Juergens; Solange Peters; Elisa Minenza; John M Wrangle; Delvys Rodriguez-Abreu; Hossein Borghaei; George R Blumenschein; Liza C Villaruz; Libor Havel; Jana Krejci; Jesus Corral Jaime; Han Chang; William J Geese; Prabhu Bhagavatheeswaran; Allen C Chen; Mark A Socinski
Journal:  N Engl J Med       Date:  2017-06-22       Impact factor: 91.245

2.  Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.

Authors:  M Choi; H Kadara; J Zhang; E R Parra; J Rodriguez-Canales; S G Gaffney; Z Zhao; C Behrens; J Fujimoto; C Chow; K Kim; N Kalhor; C Moran; D Rimm; S Swisher; D L Gibbons; J Heymach; E Kaftan; J P Townsend; T J Lynch; J Schlessinger; J Lee; R P Lifton; R S Herbst; I I Wistuba
Journal:  Ann Oncol       Date:  2017-01-01       Impact factor: 32.976

3.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

4.  Reporting recommendations for tumor marker prognostic studies (REMARK).

Authors:  Lisa M McShane; Douglas G Altman; Willi Sauerbrei; Sheila E Taube; Massimo Gion; Gary M Clark
Journal:  J Natl Cancer Inst       Date:  2005-08-17       Impact factor: 13.506

5.  Effects of cigarette smoke extract on primary activated T cells.

Authors:  Claudia P Hernandez; Kevin Morrow; Cruz Velasco; Dorota D Wyczechowska; Amarjit S Naura; Paulo C Rodriguez
Journal:  Cell Immunol       Date:  2013-04-22       Impact factor: 4.868

6.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

7.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes.

Authors:  Vonn Walter; Xiaoying Yin; Matthew D Wilkerson; Christopher R Cabanski; Ni Zhao; Ying Du; Mei Kim Ang; Michele C Hayward; Ashley H Salazar; Katherine A Hoadley; Karen Fritchie; Charles J Sailey; Charles G Sailey; Mark C Weissler; William W Shockley; Adam M Zanation; Trevor Hackman; Leigh B Thorne; William D Funkhouser; Kenneth L Muldrew; Andrew F Olshan; Scott H Randell; Fred A Wright; Carol G Shores; D Neil Hayes
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

9.  Comprehensive genomic characterization of squamous cell lung cancers.

Authors: 
Journal:  Nature       Date:  2012-09-09       Impact factor: 49.962

10.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

View more
  55 in total

1.  Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma.

Authors:  Janis V de la Iglesia; Robbert J C Slebos; Laura Martin-Gomez; Xuefeng Wang; Jamie K Teer; Aik Choon Tan; Travis A Gerke; Garrick Aden-Buie; Tessa van Veen; Jude Masannat; Ritu Chaudhary; Feifei Song; Michelle Fournier; Erin M Siegel; Matthew B Schabath; J Trad Wadsworth; Jimmy Caudell; Louis Harrison; Bruce M Wenig; Jose Conejo-Garcia; Juan C Hernandez-Prera; Christine H Chung
Journal:  Clin Cancer Res       Date:  2019-12-17       Impact factor: 12.531

Review 2.  Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer.

Authors:  Eric A Engels
Journal:  Am J Transplant       Date:  2019-07-08       Impact factor: 8.086

Review 3.  Antitumour immunity regulated by aberrant ERBB family signalling.

Authors:  Shogo Kumagai; Shohei Koyama; Hiroyoshi Nishikawa
Journal:  Nat Rev Cancer       Date:  2021-01-18       Impact factor: 60.716

Review 4.  The Need to Prioritize and Re-prioritize Palliative Care Options: Smoking Cessation as a Case-in-Point.

Authors:  Konstantinos Leventakos; Anna J Schwecke; Erin Deering; Elizabeth Cathcart-Rake; Anna C Sanh; Aminah Jatoi
Journal:  Curr Treat Options Oncol       Date:  2019-03-22

5.  HIV Modifies the Effect of Tobacco Smoking on Oral Human Papillomavirus Infection.

Authors:  Babatunde Y Alli; Robert D Burk; Mahnaz Fatahzadeh; Julie Kazimiroff; Robert M Grossberg; Richard V Smith; Thomas J Ow; Mauricio Wiltz; Jacqueline Polanco; Marie-Claude Rousseau; Belinda Nicolau; Nicolas F Schlecht
Journal:  J Infect Dis       Date:  2020-07-23       Impact factor: 5.226

6.  The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.

Authors:  Mei Jiang; Aline F Fares; Daniel Shepshelovich; Ping Yang; David Christiani; Jie Zhang; Kouya Shiraishi; Brid M Ryan; Chu Chen; Ann G Schwartz; Adonina Tardon; Sanjay Shete; Matthew B Schabath; M Dawn Teare; Loic Le Marchand; Zuo-Feng Zhang; John K Field; Hermann Brenner; Nancy Diao; Juntao Xie; Takashi Kohno; Curtis C Harris; Angela S Wenzlaff; Guillermo Fernandez-Tardon; Yuanqing Ye; Fiona Taylor; Lynne R Wilkens; Michael Davies; Yi Liu; Matt J Barnett; Gary E Goodman; Hal Morgenstern; Bernd Holleczek; Sera Thomas; M Catherine Brown; Rayjean J Hung; Wei Xu; Geoffrey Liu
Journal:  Lung Cancer       Date:  2020-12-04       Impact factor: 5.705

7.  FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.

Authors:  Huazhen Liang; Chunning Zhang; Chaoming Li; Changguo Li; Yanli Wang; Huaming Lin
Journal:  Biosci Rep       Date:  2021-07-30       Impact factor: 3.840

8.  Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models.

Authors:  Nicole D Facompre; Pavithra Rajagopalan; Varun Sahu; Alexander T Pearson; Kathleen T Montone; Claire D James; Frederico O Gleber-Netto; Gregory S Weinstein; Jalal Jalaly; Alexander Lin; Anil K Rustgi; Hiroshi Nakagawa; Joseph A Califano; Curtis R Pickering; Elizabeth A White; Bradford E Windle; Iain M Morgan; Roger B Cohen; Phyllis A Gimotty; Devraj Basu
Journal:  Int J Cancer       Date:  2020-07-06       Impact factor: 7.396

Review 9.  Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma.

Authors:  Teresa Magnes; Sandro Wagner; Dominik Kiem; Lukas Weiss; Gabriel Rinnerthaler; Richard Greil; Thomas Melchardt
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

10.  In silico analysis identifies neuropilin-1 as a potential therapeutic target for SARS-Cov-2 infected lung cancer patients.

Authors:  Song Hu; Zheyu Hu; Jiajia Qin; Chuwen Lin; Xuan Jiang
Journal:  Aging (Albany NY)       Date:  2021-06-24       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.